Specialised Therapeutics Collaborated with Akeso and CTTQ-Akeso to Commercialize New Anti-PD1 Antibody in Australia and Southeast Asia
Shots:
- ST will lead the marketing, regulatory & distribution activities in its key regions of Australia, Singapore & across Southeast Asia. CTTQ-Akeso holds the rights of conducting any development work related to Anniko & also retains all rights to product manufacture & supply
- Anniko, an anti-PD1 mAb was approved in China for advanced r/r cHL, 1L treatment of LA or metastatic sq. NSCLC in combination with CT & is currently under regulatory review in the US & China for nasopharyngeal cancer
- The clinical studies are ongoing for multiple cancers in China & Australia. Four bispecific Ab drugs developed by Akeso, incl. cadonilimab, ivonescimab, PD-1/LAG-3 & TIGIT/TGF-beta bispecific Abs have been brought to market or are in clinical development
Ref: PR Newswire | Image: Specialised Therapeutics
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
